(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.10%) $79.08
(5.02%) $2.03
(0.06%) $2 312.30
(0.66%) $26.93
(0.85%) $963.00
(-0.11%) $0.932
(-0.22%) $11.01
(-0.02%) $0.798
(0.27%) $93.51
Quarter results today
(bmo 2024-05-02)
Expected move: +/- 8.19%
Live Chart Being Loaded With Signals
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function...
Stats | |
---|---|
Today's Volume | 86 933.00 |
Average Volume | 303 626 |
Market Cap | 41.68M |
EPS | $0 ( 2024-03-21 ) |
Next earnings date | ( $-0.460 ) 2024-06-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.660 |
ATR14 | $0.00700 (0.46%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-29 | Shaw Kevin G. | Buy | 93 900 | Employee Stock Option (Right to Buy) |
2024-03-29 | Richman Michael | Buy | 244 400 | Employee Stock Option (Right to Buy) |
2024-03-29 | Myint Han | Buy | 93 900 | Employee Stock Option (Right to Buy) |
2024-03-29 | Mayer Timothy | Buy | 93 900 | Employee Stock Option (Right to Buy) |
2024-03-29 | Langermann Sol | Buy | 93 900 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 6 167 538 | Sell: 82 463 |
Volume Correlation
NextCure Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
NextCure Inc Correlation - Currency/Commodity
NextCure Inc Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-3.68M (0.00 %) |
EPS: | $-2.25 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-3.68M (0.00 %) |
EPS: | $-2.25 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-4.48M (0.00 %) |
EPS: | $-2.50 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-2.51 |
Financial Reports:
No articles found.
NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators